News | January 05, 2023
Biocytogen and Hansoh Pharma announce an antibody license agreement
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Subscribe To Our Newsletter & Stay Updated
